News 
Market Data 
Discover
Replies to post #1636 on Eastgate Biotech Corp (fka ETBI)
05/02/17 2:05 AM
05/02/17 9:07 AM
The OMNI Centres are pulling in $2,000,000 in US dollars each and also provide STEM Cell treatments.
First and Foremost lets look at what $ETBI does on a Global Scale:
Canada: Research laboratory, main office, and production facilities
US: Distribution
Serbia: Production and distribution for East Europe
Brazil: Production and distribution for South America
Bosnia and Herzegovina: Distribution
I found an interesting website that featured many products people don't know $ETBI actually sells called supplementsandherbs.com
Supplements and Herbs Inc
492 Champagne Drive,
North York, ON, M3J 2T9 Canada
mail@nanoessentials.ca
Phone: +1 519 749 1925 |
Fax: +1 905 695 9193
EastGate Biotech
488 Champagne Dr,
North York, ON, M3J 2T9, Canada
Phone: +1 647 692 0652
Fax: +1 905 695 9193
A reverse-looked-up of all the domain neighbors sharing the same IP/subnet as supplementsandherbs.com reveals something rather interesting:
bonustravel.ca
http://candida-kandida.com
http://catalinaqualitymanagement.com
http://domacica.com
http://domacica.net
http://drhasanagic.com
http://dubiozakolektiv.com
http://eastgatebiotech.com
http://eastgatepharmaceuticals.com
http://edrops.info
egp.im
http://ekapi.org
http://ekcema.com
http://eserihija.com
http://glucosesos.com
http://hasanagic.com
http://hasanagic.org
http://hepatal.com
http://jetra.net
http://jetra.org
jjj.im
http://lwnp.com
nanoessentials.ca
natural-e.ca
http://okbz.com
http://oyrolimoksi-ecoli.com
http://prirodnamedicina.com
http://supplementsandherbs.com
http://theurinarytractinfections.com
http://uljecrnogkima.com
http://utidrops.com
vedran.ca
http://zrke.com
THESE ARE ALL RELATED BUSINESSES.
Meaning one of two things. $ETBI has many revenue streams being set-up and coming in the future, many companies that could be acquired or bought out or these are already in the process of being announced in the future and have already been in the works of being acquired...or could not mean much...but I highly doubt that wink
It should be noted that before $ETBI was a Biotech company it was an Acquisition company so many of these could be past acquisitions. A quick look at them shows that MANY are still doing business, reflecting possible future revenue streams if they haven't yet been acquired.
Then they became a Bio acquisition company which explains many of their current products:
On May 22, 2012, we finalized a Patent Acquisition Agreement ("Acquisition Agreement") to acquire certain products, formulas, processes, proprietary technology and/or patents and patent applications related to pharmaceutical, nutraceutical, food supplements and consumer health products (collectively referred to as the "Acquired Products").
Such as:
Product Overview (As of 2016 10K)
Our goal is to work towards development of novel patentable formulations of pharmaceutical and natural products. The following depicts those products we plan to develop. However, we are in the early stages of research and there is no assurance that we will be able to finalize and market any commercially viable products.
Pharmaceutical Products in development
Lorazepam oral spray intended for treatment of acute seizures and based on our proprietary self-nanoemulsifying composition.
Ketoconazole 2% topical ointment intended for treatment of superficial fungal infections and based on use of our proprietary solubilization platform.
Metformin chewable/sublingual tablet based on proprietary composition and intended to allow effective taste masking of incorporated Metformin.
Natural products and dietary supplements in development
E-DROPS NANO – self-nanoemulsifying composition containing natural essential oils for oral administration.
(Already being sold)
\
PURALEN - self-emulsifying composition of essential oils for oral administration.
GLUCORA – soft gelatin capsules with combination of plant extract (standardized Banaba leaf extract, containing 18% of Corosolic acid) and lipoic acid in proprietary self-nanoemulsifying composition.
(Already being sold and received massive orders last year profits of which could be shown on the next 10K)
https://www.thestreet.com/story/13559117/2/eastgate-biotech-announces-that-it-has-received-a-substantial-order-for-glucora-its-natural-glucose-management-product.html
\
URBAN POWER – soft gelatin capsules with combination of plant extracts (standardized Ursolic acid from Sage and Banaba leaf extract with 18% of Corosolic acid) in proprietary self-nanoemulsifying composition.
VITAMIN D3 NANOEMULSION – Nanoemulsion with Cholecalciferol (vitamin D3).
(Already being sold)
\
CLEANEZZE – Hand sanitizer containing essential oil.
(Already being sold)
\
Interestingly enough I was able to even find coupons as recently as May 1st, 2017 for some of these products:
HomeHealthNutritionVitaminsEastGate Pharmaceuticals Coupons & Deals - May 1, 2017
www.dontpayfull.com/at/nano-essentials.com?c=8161699#c8161699
Many of the products are on the front page of the supplementsandherbs.com website (which I may add is a very sought out URL name) which makes me wonder...does $ETBI also own this company? Hmmmm :)
Products ready to be launched:
Hepatal
Our Nano Hepatal Herbal Drops will help to detoxify the liver and restore normal liver function
ShieldX
ShieldX chewing tablets help protect you against all too common sources of radiation, such as x-rays, CT scans, airport scanners and similar devices. Plus, ShieldX ingredients help restore cell membrane damage and mitochondria as well as eliminate excessfree radicals, caused by widespread ionizing radiation exposure. ShieldX can also help restore damaged disulfide thiol bonds, critical for proper functioning of the body’s biochemical systems.
In October 2012, our CEO, Anna Gluskin, contributed to the company the corporate entity Eastgate Pharmaceuticals Inc., a Province of Ontario, Canada corporation, of which Ms. Gluskin was the sole shareholder, officer and director. Thus, Eastgate Pharmaceuticals became and will operate as our wholly owned subsidiary. Initially, we deposited into Eastgate Pharmaceuticals the $100,000 proceeds from a demand promissory note for use by the company. We anticipate that we may conduct many of our future operations in Canada through the subsidiary.
Oh did I mention they are only using ingredients pre approved by the FDA? And are applying for an NDA as stated in their last 10K?
Our self-emulsifying drug delivery technology includes two different approaches that we believe could ultimately improve solubility of poorly soluble compounds and provide new methods of delivery.
These perceived approaches consist of
(i) a self-nanoemulsifying vehicles for oral or topical use
(ii) a technological approach intended to improve solubility of incorporated compounds.
We expect that our technologies can be applied to products based on natural compounds and well-established pharmaceuticals with known biological activities.
In developing our proposed products, we intend to use modern delivery technologies. Some examples are:
- Nanoemulsification and self-nanoemulsification;
- Polymer-lipid mixed micelles; and
- Solubility improvement of poorly soluble compounds for molecules with known biological activity and well established safety profiles.
We are presently applying our technology only to known pharmaceutical compounds that have been previously approved by the Food and Drug Administration (“ FDA ”). Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act permits a company to apply for FDA approval of a New Drug Application (“ NDA ”) without conducting the full complement of safety and efficacy trials. An applicant under Section 505(b)(2) may use the original filer’s information and rely on published studies to demonstrate the safety and effectiveness of the new drug based on a known compound. Because we intend to apply our technology only to previously approved pharmaceutical compounds, we believe that Section 505(b)(2) could possibly be available to us. If we are permitted to use Section 505(b)(2), it would likely decrease requirements for preclinical investigations and clinical testing and accelerate the overall approval time for our products, although there can be no assurance of this.
Some of our proposed products under development are based on existing natural compounds. Many of these proposed products are made of essential oils and plant extracts. Our proposed products comprise excipients listed in the FDA “Inactive Ingredients Guide” that we believe are safe and approved for human consumption. Additionally, we believe that these proposed products can be manufactured using common equipment. We anticipate that we will be able to apply self-emulsifying technologies for development of a variety of pharmaceuticals and natural products for different applications.
Let's look at the patents:
$ETBI patents:
Sublingual Insulin Formulation:
US 61/947,678 Title: Pharmaceutical Composition for Transmucosal Delivery
US 61/947,698 Title: Treatment of Diabetes and Metabolic Syndrome
Intraoral Lorazepam Spray for treatment of acute seizures:
PCT/C2014/000126 Title: Pharmaceutical Composition for Transmucosal Administration of Benzodiazepines
PCT/CA2014/000127 Title: Pharmaceutical Composition For Enhanced Transmucosal Administration of Benzodiazepines
https://www.google.com/patents/US20150250856?cl=en21
The first two are an ORAL solution to Diabetes, that's right folks, say goodbye to Needles :-O
I think that's a pretty big deal, don't you?
$ETBI's Insulin Tablet:
Diabetes EGP-1214 - INTRAORAL (SUBLINGUAL) INSULIN TABLET BY EASTGATE BIOTECH
The Intraoral Insulin Tablet:
EGP-1214, the EastGate Biotech’s flagship product in the field of diabetes and metabolic syndrome. It is a compressed tablet containing human recombinant insulin and designed for sublingual administration. The tablet contains relatively small amount of insulin (1 mg per tablet). The tablet is administered sublingually (under the tongue) where it dissolves and provides transmucosal delivery of the peptide for blood glucose management. The tablet should not be swallowed to avoid degradation of insulin in the stomach.
The intraoral insulin tablet designed for the treatment of early stages of Type 2 diabetes as well as for pre-diabetes. Providing additional exogenic insulin to Type 2 diabetes patients should slow down the rate of pancreas deterioration and improve glycemic control. The gland can respite and the disease progress may decelerate. The tablet can be used as an add-on medicine in a combination treatment with other oral antidiabetic drugs, commonly prescribed for treatment of Type 2 diabetes.
The tablet can also be employed to treat pre-diabetes; due to exaggerating pandemic growth of diabetes amongst young and aging adult age groups, patients are looking for a non-invasive means to treat and counteract the disease early enough.
Current research has shown that the administration of insulin at earlier stages of Type 2 diabetes mellitus has positive effects and is now beginning to be included in the standard treatment regimens. While the benefits can be significant, some patients are hesitant to introduce injections into their daily routine. The addition of an effective non-injectable insulin dosage form to the anti-diabetes treatment regimen will have significant benefits in terms of compliance among patients.
Drug delivery via the buccal and sublingual mucosa:
BENEFITS AND ADVANTAGES OF SUBLINGUAL DELIVERY
-Pre-systemic metabolism of the peptide in the GI and liver is avoided
-Good accessibility; the drug is in direct contact with the mucosa, avoiding significant dilution;
-Formation of a high gradient across the mucosa allowing drug diffusion into the underlying tissue
-High level of vascularization in sublingual area
-Small variations of pH (not as in gastrointestinal tract)
-Buccal and Sublingual enzymatic activity is mainly intracellular and less pronounced than in other parts of GI tract; practically no protease activity in saliva
-Non-invasive blood sugar maintenance
-Low probability of hypoglycemic events
INITIAL EXPERIMENTS
Initial experiments of EGP-1214 demonstrated that the developed sublingual insulin tablet is easy and convenient to use; does not irritate the sublingual mucosa and has a fast and reproducible onset of glucose lowering action (within 30 minutes). The transmucosal penetration of EGP-1214 was clearly confirmed by the decrease of C-peptide concentration in blood.
From 2010 to 2020, the number of people with diabetes is expected to rise by another 1.2 million, bringing the total to about 3.7 million. These increases escalate the proportion of the total population with diabetes from 4.2% in 2000 to 7.3% in 2010 and to 9.9% by 2020
DIABETES CAN LEAD TO SERIOUS COMPLICATIONS AND PREMATURE DEATH:
• 80% of patients with diabetes die from a heart attack or a stroke
• 42% of new kidney dialysis patients in 2004 had diabetes
• Diabetes is the single leading cause of blindness
• 7 of 10 non-traumatic limb amputations are the result of diabetes complications
• 25% of people with diabetes suffer from depression
• The life expectancy for people with type 1 diabetes may be shortened by ~15 years
• The life expectancy for people with type 2 diabetes may be shortened by 5-10 years
HUMAN INSULIN IS THE MOST SAFE (as long as hypoglycemia avoided) AND EFFECTIVE MEDICINE FOR DIABETES TREATMENT
LACK OF CONVENIENT NON-INJECTABLE DOSAGE FORMS PRECLUDES WIDE USE OF INSULIN FOR EARLY STAGES OF DIABETES
Another sticky already mentioned the first clinic the opened up and the fact they will be announcing 4 to 5 more.
Also the possibility these clinics will be doing a few million in sales per year.
With this in mind we could anticipate evenues of 10 to 15 million or more...especially since stem cells are involved.
It was also mentioned that they will be franchising these unique surgery and aging centers and sounds like they are looking at having 15-20 or more in the mix this year alone.
Another thing to discuss is the Northbridge financial filing on April 1, 2017:
EastGate Biotech Corp. (the “Company”) entered into a Settlement Agreement with Northbridge Financial, Inc. (“Northbridge”), whereby Northbridge acquired liabilities of the Company in the amount of $208,000 (the “Debt”), which was owed by the Company to third parties related to debts related to the Company’s outstanding liabilities. The Company and Northbridge then entered into an Order Granting Approval of the Settlement Agreement, and Northbridge converted the Debt pursuant to a 3(a)(10) exemption into 40,000,000 shares of the Company’s common stock.
That's 40,000,000 shares on April 1st
From April 1st to the 25th the PPS dropped tremendously then the PR goes out and bam it starts going back up. My train of thought is, if the company didn't convert all their shares they are certainly waiting for much much higher at this point IMO.
Not to mention Northbridge acquired all their outstanding liabilities related to its debt that it owed, in exchange for those shares. I mean if that's not a win win I don't know what is lol
Now for the Warrants:
$ETBI has something in common with 5 other big runners:
$USRM: 002 to .17
$OWCP: 003 to $3.00
$GIGL: 0018 to .26
$DOLV: 0001 to .084
$MYDX: 0012 to .0224
They all have warrants.
As of September 30, 2016, the Company had 41,164,901 warrants to purchase common stock. All outstanding warrants have a weighted average price of $0.07 per share and have a weighted average remaining life of 2.81 years.
The following table summarizes warrants that are issued, outstanding and exercisable
Warrants Issued & Outstanding:
March 14, 2019
3,495,000
3,495,000
0.25
March 21, 2019
3,480,000
3,480,000
0.25
June 6, 2019
2,022,300
2,022,300
0.05
October 16, 2019
150,000
150,000
0.04
December 31, 2019
8,125,000
8,125,000
0.04
January 5, 2020
8,146,225
8,146,225
0.04
August 19, 2020
125,000
125,000
October 6, 2020
15,621,376
16,171,627
41,164,901
41,715,152
Gunpowder Capital the most recent company to acquire warrants in the company only deals with legit high profile companies that are profitable such as RocktheVapor.com among their clientele.
It must also be noted that Gunpowder Capital does not receive shares from $ETBI until they are listed on the Canadian Exchange.
https://docs.google.com/viewer?a=v&pid=sites&srcid=ZGVmYXVsdGRvbWFpbnxwZGZndW58Z3g6MjhkOTJiMmNkMzE5Y2EwNQ
[color=red]Let's discuss some other upcoming catalysts for $ETBI:
The company is expecting audited financials this year and the removal of the stop sign which will bring in even more investors since most brokers won't let you buy a stock with a stop sign (Except Schwab which is my personal favorite)
NT 10-K for 2016 is expected soon as well, with profits from the sales of its products more than likely showing on this one.
The company is also planning to enlist on the Canadian Exchange through GunPowder Capital
The Acquisition of OMNI Surgery and Anti-Aging Centres
Speaking of which, let's talk about $ETBI's recent acquisition of an OMNI Surgery and Anti-Aging Centre:
www.eastgatebiotech.com/investors/press-releases/omni/
The new OMNI Surgery and Anti-Aging Centre is already having events as seen by their FB and producing live videos:
Spring Awakening event Spring Awakening Event May 4th at the Omni Surgery + Anti-Aging Centre
https://www.facebook.com/omnisurgery/
The global anti-aging market is growing at a CAGR of 7.8% between 2013 and 2019. With the market’s value being 122.3 billion in 2013, it is expected to reach US$191.7 billion by the end of 2019. Statistics regarding the same have been provided in a research report by Transparency Market Research (TMR), titled “Anti-aging Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019”, on sale on TMR’s website.
http://www.transparencymarketresearch.com/pressrelease/anti-aging-market.htm
The OMNI Centres are pulling in $2,000,000 in US dollars each and also provide STEM Cell treatments.
\
Remember the company is due to file their 10K for 2016 although these revenues won't be reflected on that one, it surely will be on next year's 10K and EOY filings but I am sure $ETBI will update as progress is made.
Also how about the recent JV with AC Nova? That's a nice little tidbit too smile
http://www.eastgatebiotech.com/investors/press-releases/eastgate-biotech-corporation-and-ac-nova-technologies-ati-pharma-announce-joint-venture/
http://www.atipharma.com
AC Nova's products are available at Canadian Safeway stores, which is a pretty BIG deal.
05/02/17 6:30 PM
AI
